[1] Pennathur A, Gibson MK, Jobe BA, et al.Oesophageal carcinoma[J]. Lancet, 2013, 381(98) : 400-412.
[2] Kojima T, Doi T. Immunotherapy for Esophageal Squamous Cell Carcinoma[J]. Curr Oncol Rep, 2017, 19(5) : 33-36.
[3] Kudo T, Hamamoto Y, Kato K, et al.Nivolumab treatment for oesophageal squamous-cell carcinoma : an openlabel, multicentre, phase 2 trial[J] . Lancet Oncol , 2017, 18(5): 631-639.
[4] Lote H, Cafferkey C, Chau I, et al.PD-1 and PD-L1 blockade in gastrointestinal malignancies[J]. Cancer Treat Rev, 2015, 41(10) : 893-903.
[5] Lim JS, Sundar R, Chénardpoirier M, et al.Emerging bio-markers for PD-1 pathway cancer therapy[J]. Biomark Med, 2017, 11(1) : 53-67.
[6] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(14): 252-264.
[7] Schwartz RH.Costimulation of T lymphocytes:the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy[J]. Cell, 1992, 71(7) : 1065-1068.
[8] Haanen JB, Robert C.Immune checkpoint inhibitors[J]. Prog Tumor Res, 2015, 42 : 55-66.
[9] Azuma T, Yao S, Zhu G, et al.B7-H1 is a ubiquitous an-tiapoptotic receptor on cancer cells[J]. Blood, 2008, 111(7) : 3635-3643.
[10] Ralph C, Elkord E, Burt DJ, et a1. Moduladon of 1ymphocyte regIllation for cancer therpy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J]. Clin Cancer Res, 20l0, 16(5): 1662-1672.
[11] Hodi FS, Day SJ, Mcdennolt DF, et a1. Impmved survival with ipimumab in patients with metastatic melaIloma[J]. N Engl J Med, 2010, 363(8): 711-723.
[12] Jin Zhaohui, Yoon, HH.The promise of PD-1 inhibitors in gastro-esophageal cancers: Microsatellite instability PD-L1[J]. J Gastrointest Oncol, 2016, 7(5) : 771-788.
[13] Kudo T, Hamamoto Y, Kato K, et al.Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(5) : 631-639.
[14] Kato K, Satoh T, Muro K, et al.Opdivo (Nivolumab) Demonstrates a Significant Extension in Overall Survival Versus Chemotherapy in Patients with Unresectable Advanced or Recurrent Esophageal Cancer in Phase III Clinical Study[J]. Gastric Cancer, 2019, 22(2): 344-354.
[15] Shah MA, Kojima T, Hochhauser D, et al.Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol , 2019, 5(4) : 546-550.
[16] Kojima T, Muro K, Francois E, et al.Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: the phase III KEYNOTE-181 study[J]. J Clin Oncol, 2019, 37(suppl 4): 2.
[17] Wang X, Zhang B.Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody[J].Thorac Cancer, 2019, 10(6): 1395-1401.
[18] Huang J, Xu B, Mo H, et al.Safety, activity, and biomarkers of SHR-1210, an Anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6): 1296-1304.
[19] Kono K, Iinuma H, Akutsu Y, et al.Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens[J]. J Transl Med, 2012, 141(10): 141-143.
[20] Kono K, Mizukami Y, Daigo Y, et al.Vaccination with multiple peptides derived from novel cancertestis antigens can induce specific Tcell responses and clinical responses in advanced esophageal cancer[J]. Cancer Sci, 2009, 100(8): 1502-1509.
[21] Kojima T, Doi T. Immunotherapy for Esophageal Squamous Cell Carcinoma[J]. Current Oncology Reports, 2017, 19(5): 33.
[22] Cecco S, Muraro E, Giacomin E, et al.Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives[J]. Curr Cancer Drug Targets, 2011, 11(1) : 85-102.
[23] Chen K, Cheng G, Zhang F, et al.Prognostic significance of pro-grammed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma[J]. Oncotarget, 2016, 7(21): 30772-30780.
[24] Lim SH, Hong M, Ahn S, et al.Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemora-diotherapy in patients with squamous oesophageal cancer[J]. Eur J Cancer, 2016, 52: 1-9. |
